Shares of Celcuity Inc. (NASDAQ:CELC - Get Free Report) dropped 4.6% during trading on Friday . The company traded as low as $16.80 and last traded at $16.85. Approximately 37,976 shares changed hands during mid-day trading, a decline of 82% from the average daily volume of 215,491 shares. The stock had previously closed at $17.66.
Wall Street Analyst Weigh In
CELC has been the subject of a number of analyst reports. Stifel Nicolaus restated a "buy" rating and set a $40.00 price objective on shares of Celcuity in a report on Thursday. HC Wainwright reiterated a "buy" rating and issued a $27.00 price objective on shares of Celcuity in a research report on Thursday. Needham & Company LLC reaffirmed a "buy" rating and issued a $24.00 price target on shares of Celcuity in a research note on Thursday. Finally, Craig Hallum restated a "buy" rating and set a $27.00 price objective (up from $25.00) on shares of Celcuity in a report on Thursday.
Check Out Our Latest Analysis on Celcuity
Celcuity Trading Down 5.1 %
The company has a debt-to-equity ratio of 0.26, a quick ratio of 13.43 and a current ratio of 13.43. The stock has a market cap of $510.34 million, a price-to-earnings ratio of -6.03 and a beta of 0.87. The business has a 50-day simple moving average of $17.95 and a two-hundred day simple moving average of $15.62.
Celcuity (NASDAQ:CELC - Get Free Report) last announced its earnings results on Wednesday, March 27th. The company reported ($0.65) EPS for the quarter, topping the consensus estimate of ($0.71) by $0.06. As a group, research analysts forecast that Celcuity Inc. will post -2.93 EPS for the current year.
Institutional Investors Weigh In On Celcuity
Large investors have recently made changes to their positions in the stock. Perceptive Advisors LLC bought a new position in shares of Celcuity in the 4th quarter valued at about $21,583,000. Baker BROS. Advisors LP raised its stake in Celcuity by 189.9% in the first quarter. Baker BROS. Advisors LP now owns 1,552,478 shares of the company's stock valued at $33,534,000 after buying an additional 1,017,000 shares during the period. Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in shares of Celcuity in the first quarter valued at approximately $3,545,000. Commodore Capital LP boosted its stake in shares of Celcuity by 3.6% during the 4th quarter. Commodore Capital LP now owns 1,754,704 shares of the company's stock worth $25,566,000 after acquiring an additional 60,563 shares during the period. Finally, Trust Point Inc. acquired a new position in shares of Celcuity during the 4th quarter worth approximately $297,000. Institutional investors and hedge funds own 63.33% of the company's stock.
About Celcuity
(
Get Free Report)
Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.
Further Reading
Before you consider Celcuity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Celcuity wasn't on the list.
While Celcuity currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
